Current HPV-DNA testing in population screening for cervical cancer might have had it best time. A new test originating from Radboudumc gives a decisive answer within four days.
Related news items
Aftermovie Investment Day 2022 and a new date for 2023!13 December 2022
Over 100 scientists, investors, and entrepreneurs came together to accelerate innovation in healthcare by creating new business opportunities and forging strong public-private partnerships.read more
Successful matchmaking at Radboudumc Investment Day7 October 2022
On the 5th of October, over 100 scientists, investors and entrepreneurs came together at the second Radboudumc Investment Day, jointly hosted by Radboudumc, Oost NL and Briskr.read more
Innovation by Predica Diagnostics BV improves cervical cancer screening26 July 2022
A joint financing round from ION+2 and the Thematic Technology Transfer Medtech Fund (TTT Medtech) allows the further development of molecular diagnostic tests for different cancers by Predica Diagnostics (Nijmegen, NL).read more